Patents by Inventor Jason K. Pinkstaff

Jason K. Pinkstaff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS, ASSOCIATED FORMULATIONS AND USES THEREOF
    Publication number: 20220251526
    Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lyso-somal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 11, 2022
    Inventors: SAEED MOSHASHAEE, JASON K. PINKSTAFF, ADAM SHAYWITZ, NATALIE CIACCIO
  • Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
    Patent number: 11345904
    Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 31, 2022
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Saeed Moshashaee, Jason K. Pinkstaff, Adam Shaywitz, Natalie Ciaccio
  • USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS
    Publication number: 20220160836
    Abstract: The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.
    Type: Application
    Filed: December 3, 2021
    Publication date: May 26, 2022
    Inventors: Charles A. O'Neill, Todd M. Oppeneer, Jason K. Pinkstaff
  • Use of C-type natriuretic peptide variants to treat osteoarthritis
    Patent number: 11202819
    Abstract: The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: December 21, 2021
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Charles A. O'Neill, Todd M. Oppeneer, Jason K. Pinkstaff
  • TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS, ASSOCIATED FORMULATIONS AND USES THEREOF
    Publication number: 20200297821
    Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 24, 2020
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: SAEED MOSHASHAEE, JASON K. PINKSTAFF, ADAM SHAYWITZ, NATALIE CIACCIO
  • USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS
    Publication number: 20190247467
    Abstract: The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.
    Type: Application
    Filed: December 8, 2016
    Publication date: August 15, 2019
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: CHARLES A. O'NEILL, TODD M. OPPENEER, JASON K. PINKSTAFF
  • Anti-CD70 antibody drug conjugates
    Patent number: 10208123
    Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: February 19, 2019
    Assignee: Ambrx, Inc.
    Inventors: Richard S. Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason K. Pinkstaff
  • Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides
    Publication number: 20150152187
    Abstract: This invention relates to anti-prostate-specific membrane antigen antibodies (?PSMA) and ?PSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 4, 2015
    Applicant: Ambrx, Inc.
    Inventors: Ying Sun, Ning Zou, Amha Hewet, Jason K. Pinkstaff, Shailaja Srinagesh, Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck
  • Anti-CD70 Antibody Drug Conjugates
    Publication number: 20150141624
    Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 21, 2015
    Applicant: AMBRX, INC.
    Inventors: Richard S. Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason K. Pinkstaff
  • Synthetic internal ribosome entry sites and methods of identifying same
    Patent number: 7468275
    Abstract: Synthetic and isolated translational regulatory elements, including oligonucleotides that have translational enhancing activity, internal ribosome entry site (IRES) activity, or translational inhibitory activity, and multimers of such translational regulatory elements are provided. In addition, compositions that include such translational regulatory elements are provided, as are methods of using the translational regulatory elements.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: December 23, 2008
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Geoffrey Owens, Jason K. Pinkstaff, Leslie Krushel, Wei Zhou
  • Synthetic internal ribosome entry sites and methods of identifying same
    Publication number: 20040043468
    Abstract: Synthetic and isolated translational regulatory elements, including oligonucleotides that have translational enhancing activity, internal ribosome entry site (IRES) activity, or translational inhibitory activity, and multimers of such translational regulatory elements are provided. In addition, compositions that include such translational regulatory elements are provided, as are methods of using the translational regulatory elements.
    Type: Application
    Filed: November 27, 2002
    Publication date: March 4, 2004
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Geoffrey Owens, Jason K. Pinkstaff, Leslie Krushel, Wei Zhou